Timothy L. Cover

Dr. Timothy L. Cover

Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
orcid

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 1995 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
JAJohn C. Atherton
John C. Atherton
PCPing Cao
Ping Cao
RPRichard M. Peek
Richard M. Peek
MTMurali K. R. Tummuru
Murali K. R. Tummuru
MBMartin J. Blaser
Martin J. Blaser
TCTimothy L. Cover
Timothy L. Cover
Approximately 50% of Helicobacter pylori strains produce a cytotoxin, encoded by vacA, that induces vacuolation of eukaryotic cells. Analysis of a clinically isolated tox strain (Tx30a) indicated secretion of a 93-kDa product from a 3933-base pair vacA open reading frame. Characterization of 59 different H. pylori isolates indicated the existence of three different families of vacA signal sequences (s1a, s1b, and s2) and two different families of middle-region alleles (m1 and m2). All possible combinations of these vacA regions were identified, with the exception of s2/m1 (p < 0.001); this mosaic organization implies that recombination has occurred in vivo between vacA alleles. Type s1/m1 strains produced a higher level of cytotoxin activity in vitro than type s1/m2 strains; none of 19 type s2/m2 strains produced detectable cytotoxin activity. The presence of cagA (cytotoxin-associated gene A) was closely associated with the presence of vacA signal sequence type s1 (p < 0.001). Among patients with past or present peptic ulceration, 21 (91%) of 23 harbored type s1 strains compared with 16 (48%) of 33 patients without peptic ulcers; only 2 (10%) of 19 subjects harboring type s2 strains had past or present peptic ulcers (p < 0.005). Thus, specific vacA genotypes of H. pylori strains are associated with the level of in vitro cytotoxin activity as well as clinical consequences.

1 February 2007 in Gastroenterology
Verified
Journal Article
Open access
PDF file
FYFang Yan
Fang Yan
HCHanwei Cao
Hanwei Cao
TCTimothy L. Cover
Timothy L. Cover
RWRobert Whitehead
Robert Whitehead
MWM. Kay Washington
M. Kay Washington
DPD. Brent Polk
D. Brent Polk
Background & Aims: Increased inflammatory cytokine levels and intestinal epithelial cell apoptosis leading to disruption of epithelial integrity are major pathologic factors in inflammatory bowel diseases. The probiotic bacterium Lactobacillus rhamnosus GG (LGG) and factors recovered from LGG broth culture supernatant (LGG-s) prevent cytokine-induced apoptosis in human and mouse intestinal epithelial cells by regulating signaling pathways. Here, we purify and characterize 2 secreted LGG proteins that regulate intestinal epithelial cell antiapoptotic and proliferation responses. Methods: LGG proteins were purified from LGG-s, analyzed, and used to generate polyclonal antibodies for immunodepletion of respective proteins from LGG-conditioned cell culture media (CM). Mouse colon epithelial cells and cultured colon explants were treated with purified proteins in the absence or presence of tumor necrosis factor (TNF). Akt activation, proliferation, tissue injury, apoptosis, and caspase-3 activation were determined. Results: We purified 2 novel proteins, p75 (75 kilodaltons) and p40 (40 kilodaltons), from LGG-s. Each of these purified protein preparations activated Akt, inhibited cytokine-induced epithelial cell apoptosis, and promoted cell growth in human and mouse colon epithelial cells and cultured mouse colon explants. TNF-induced colon epithelial damage was significantly reduced by p75 and p40. Immunodepletion of p75 and p40 from LGG-CM reversed LGG-CM activation of Akt and its inhibitory effects on cytokine-induced apoptosis and loss of intestinal epithelial cells. Conclusions: p75 and p40 are the first probiotic bacterial proteins demonstrated to promote intestinal epithelial homeostasis through specific signaling pathways. These findings suggest that probiotic bacterial components may be useful for preventing cytokine-mediated gastrointestinal diseases.

1 May 2009 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
TCTimothy L. Cover
Timothy L. Cover
MBMartin J. Blaser
Martin J. Blaser

15 May 1995
Verified
Journal Article
Closed access
MBM J Blaser
M J Blaser
Guillermo Perez PerezGuillermo Perez Perez
Guillermo Perez Perez
HKH Kleanthous
H Kleanthous
TCTimothy L. Cover
Timothy L. Cover
RPR M Peek
R M Peek
ANA Nomura
A Nomura

10 March 2005 in Nature Reviews Microbiology
Verified
Journal Article
Closed access
TCTimothy L. Cover
Timothy L. Cover
SBSteven R. Blanke
Steven R. Blanke

6 July 1989 in New England Journal of Medicine
Verified
Journal Article
Closed access
TCTimothy L. Cover
Timothy L. Cover
RARobert C. Aber
Robert C. Aber
YERSINIA ENTEROCOLITICA is rapidly emerging worldwide as an enteric pathogen associated with a wide spectrum of clinical and immunologic manifestations. The clinical illness caused by this pathogen ranges from self-limited enterocolitis to potentially fatal systemic infection; post-infection manifestations include erythema nodosum and reactive arthritis. The organism was first described by Schleifstein and Coleman in 1939 as "an unidentified microorganism resembling Bacterium lignieri and Pasteurella pseudotuberculosis, and pathogenic for man."1 Isolates were variously named Bacterium enterocoliticum, P. X, P. pseudotuberculosis type b, Germe X, and P. pseudotuberculosis X, until 1964, when Frederiksen proposed the name Yersinia enterocolitica.2 In . . .